Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 62 for Clinical Genomics

Edit search filters
  1. Zagociguat in Participants With Melas (Prizm)

    Rochester, MN

  2. A Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of RO7248824 In Participants With Angelman Syndrome

    Rochester, MN

  3. Nicotinamide Riboside (NR) for Mitochondrial Myopathy Disorder Treatment

    Rochester, MN

  4. Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia

    Rochester, MN

  5. Mayo Clinic Health TAPESTRY: Use of Genomic Sequencing in Clinical Practice

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  6. A Study to Evaluate Food on Gastrointestinal Toxicity and The Effect of Selumetinib in Adolescents with Neurofibromatosis Type 1

    Rochester, MN

  7. Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG

    Rochester, MN

  8. 24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Adults With PMM2-CDG

    Rochester, MN

  9. A Phase I study of Epalrestat Therapy in a Single Patient with Phosphomannomutase Deficiency (PMM2-CDG)

  10. Innovative Trial for Understanding the Impact of Targeted Therapies in NF2

    Rochester, MN

.

Mayo Clinic Footer